Prediabetes-induced vascular alterations exacerbate central pathology in APPswe/PS1dE9 mice

Psychoneuroendocrinology

Volumn 48, Issue , 2014, Pages 123-135

  Ramos Rodriguez, Juan Jose ^a   Ortiz Barajas, Oscar ^a   Gamero Carrasco, Carlos ^a   de la Rosa, Pablo Romero ^a   Infante Garcia, Carmen ^a   Zopeque Garcia, Nuria ^b   Lechuga Sancho, Alfonso M ^a   Garcia Alloza, Monica ^a  

^a UNIVERSITY OF CÁDIZ   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

Alzheimer's disease; Amyloid ; Haemorrhage; Hyperinsulinemia; Insulin degrading enzyme; Microglia; Neprilysin; Prediabetes; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; TAU PROTEIN; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; PRESENILIN 1, MOUSE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INTERSTITIAL FLUID; LEARNING DISORDER; LIPID DIET; MEMORY DISORDER; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; ANIMAL; COMPLICATION; DIABETIC ANGIOPATHIES; DISEASE COURSE; DISEASE MODEL; GENETICS; HYPERINSULINISM; INSULIN RESISTANCE; MAZE TEST; MEMORY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DIABETIC ANGIOPATHIES; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HYPERINSULINISM; INSULIN RESISTANCE; MAZE LEARNING; MEMORY; MICE; MICE, TRANSGENIC; PREDIABETIC STATE; PRESENILIN-1; TAU PROTEINS;

EID: 84904874633     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2014.06.005     Document Type: Article

References (67)

1. Aso E., Semakova J., Joda L., Semak V., Halbaut L., Calpena A., Escolano C., Perales J.C., Ferrer I. Triheptanoin supplementation to ketogenic diet curbs cognitive impairment in APP/PS1 mice used as a model of familial Alzheimer's disease. Curr. Alzheimer Res. 2013, 10:290-297.
2. Barella L.F., de Oliveira J.C., Branco R.C., Camargo R.L., Gomes R.M., Mendes F.C., Miranda R.A., Gravena C., Torrezan R., Grassiolli S., de Freitas Mathias P.C. Early exposure to a high-fat diet has more drastic consequences on metabolism compared with exposure during adulthood in rats. Horm. Metab. Res. 2012, 44:458-464.
3. Becker K., Freude S., Zemva J., Stohr O., Krone W., Schubert M. Chronic peripheral hyperinsulinemia has no substantial influence on tau phosphorylation in vivo. Neurosci. Lett. 2012, 516:306-310.
4. Beckett T.L., Studzinski C.M., Keller J.N., Paul Murphy M., Niedowicz D.M. A ketogenic diet improves motor performance but does not affect beta-amyloid levels in a mouse model of Alzheimer's disease. Brain Res. 2013, 1505:61-67.
5. Bosco D., Fava A., Plastino M., Montalcini T., Pujia A. Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J. Cell. Mol. Med. 2011, 15:1807-1821.
6. Camargo N., Brouwers J.F., Loos M., Gutmann D.H., Smit A.B., Verheijen M.H. High-fat diet ameliorates neurological deficits caused by defective astrocyte lipid metabolism. FASEB J. 2012, 26:4302-4315.
7. Correia S.C., Santos R.X., Perry G., Zhu X., Moreira P.I., Smith M.A. Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease?. Ageing Res. Rev. 2011, 10:264-273.
8. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch. Neurol. 2009, 66:300-305.
9. Cruse G., Beaven M.A., Ashmole I., Bradding P., Gilfillan A.M., Metcalfe D.D. A truncated splice-variant of the FcepsilonRIbeta receptor subunit is critical for microtubule formation and degranulation in mast cells. Immunity 2013, 38:906-917.
10. de la Monte S.M., Tong M., Lester-Coll N., Plater M., Wands J.R. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J. Alzheimers Dis. 2006, 10:89-109.
11. Eckman E.A., Eckman C.B. Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. 2005, 33:1101-1105.
12. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., Eckman C.B., Tanzi R.E., Selkoe D.J., Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4162-4167.
13. Fendrick S.E., Xue Q.S., Streit W.J. Formation of multinucleated giant cells and microglial degeneration in rats expressing a mutant Cu/Zn superoxide dismutase gene. J. Neuroinflammation 2007, 4:9.
14. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 1997, Academic Press, United States.
15. Gallagher J.J., Minogue A.M., Lynch M.A. Impaired performance of female APP/PS1 mice in the Morris water maze is coupled with increased Abeta accumulation and microglial activation. Neurodegener. Dis. 2013, 11:33-41.
16. Garcia-Alloza M. Streptozotocin as a tool to induce central pathology and cognitive impairment in rodents. Streptozotocin: Uses, Mechanism of Action and Side Effects 2014, Nova Science Publishers, Inc., Hauppauge, NY. E.L. Gauthier (Ed.).
17. Garcia-Alloza M., Borrelli L.A., Thyssen D.H., Hickman S.E., El Khoury J., Bacskai B.J. Four-dimensional microglia response to anti-Aβ treatment in APP/PS1xCX3CR1/GFP mice. Intravital 2013, 2(April/May/June (2)):e25693.
18. Garcia-Alloza M., Gregory J., Kuchibhotla K.V., Fine S., Wei Y., Ayata C., Frosch M.P., Greenberg S.M., Bacskai B.J. Cerebrovascular lesions induce transient beta-amyloid deposition. Brain 2011, 134:3697-3707.
19. Garcia-Alloza M., Robbins E.M., Zhang-Nunes S.X., Purcell S.M., Betensky R.A., Raju S., Prada C., Greenberg S.M., Bacskai B.J., Frosch M.P. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 2006, 24:516-524.
20. Gorelick P.B., Nyenhuis D. Understanding and treating vascular cognitive impairment. Continuum (Minneap Minn) 2013, 19:425-437.
21. Hassing L.B., Grant M.D., Hofer S.M., Pedersen N.L., Nilsson S.E., Berg S., McClearn G., Johansson B. Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study. J. Int. Neuropsychol. Soc. 2004, 10:599-607.
22. Herculano B., Tamura M., Ohba A., Shimatani M., Kutsuna N., Hisatsune T. Beta-alanyl-l-histidine rescues cognitive deficits caused by feeding a high fat diet in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 2013, 33:983-997.
23. Heyward F.D., Walton R.G., Carle M.S., Coleman M.A., Garvey W.T., Sweatt J.D. Adult mice maintained on a high-fat diet exhibit object location memory deficits and reduced hippocampal SIRT1 gene expression. Neurobiol. Learn. Mem. 2012, 98:25-32.
24. Hiltunen M., Khandelwal V.K., Yaluri N., Tiilikainen T., Tusa M., Koivisto H., Krzisch M., Vepsalainen S., Makinen P., Kemppainen S., Miettinen P., Haapasalo A., Soininen H., Laakso M., Tanila H. Contribution of genetic and dietary insulin resistance to Alzheimer phenotype in APP/PS1 transgenic mice. J. Cell. Mol. Med. 2012, 16:1206-1222.
25. Hyman B.T. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch. Neurol. 2011, 68:1062-1064.
26. Jankowsky J.L., Slunt H.H., Gonzales V., Jenkins N.A., Copeland N.G., Borchelt D.R. APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol. Aging 2004, 25:885-892.
27. Jimenez-Palomares M., Ramos-Rodriguez J.J., Lopez-Acosta J.F., Pacheco-Herrero M., Lechuga-Sancho A.M., Perdomo G., Garcia-Alloza M., Cozar-Castellano I. Increased Abeta production prompts the onset of glucose intolerance and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2012, 302:E1373-E1380.
28. Kivipelto M., Laakso M.P., Tuomilehto J., Nissinen A., Soininen H. Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: potential for pharmacological intervention. CNS Drugs 2002, 16:435-444.
29. Knight E.M., Martins I.V., Gumusgoz S., Allan S.M., Lawrence C.B. High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice is independent of changes in amyloid and tau pathology. Neurobiol. Aging 2014, 35:1821-1832.
30. Koffie R.M., Meyer-Luehmann M., Hashimoto T., Adams K.W., Mielke M.L., Garcia-Alloza M., Micheva K.D., Smith S.J., Kim M.L., Lee V.M., Hyman B.T., Spires-Jones T.L. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4012-4017.
31. Lechuga-Sancho A.M., Arroba A.I., Frago L.M., Paneda C., Garcia-Caceres C., Delgado Rubin de Celix A., Argente J., Chowen J.A. Activation of the intrinsic cell death pathway, increased apoptosis and modulation of astrocytes in the cerebellum of diabetic rats. Neurobiol. Dis. 2006, 23:290-299.
32. Liu Z., Zhu H., Fang G.G., Walsh K., Mwamburi M., Wolozin B., Abdul-Hay S.O., Ikezu T., Leissring M.A., Qiu W.Q. Characterization of insulin degrading enzyme and other amyloid-beta degrading proteases in human serum: a role in Alzheimer's disease?. J. Alzheimers Dis. 2012, 29:329-340.
33. Luchsinger J.A., Reitz C., Patel B., Tang M.X., Manly J.J., Mayeux R. Relation of diabetes to mild cognitive impairment. Arch. Neurol. 2007, 64:570-575.
34. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63:1187-1192.
35. Maesako M., Uemura K., Kubota M., Kuzuya A., Sasaki K., Asada M., Watanabe K., Hayashida N., Ihara M., Ito H., Shimohama S., Kihara T., Kinoshita A. Environmental enrichment ameliorated high-fat diet-induced Abeta deposition and memory deficit in APP transgenic mice. Neurobiol. Aging 2012, 33(1011):e11-e23.
36. Maesako M., Uemura K., Kubota M., Kuzuya A., Sasaki K., Hayashida N., Asada-Utsugi M., Watanabe K., Uemura M., Kihara T., Takahashi R., Shimohama S., Kinoshita A. Exercise is more effective than diet control in preventing high fat diet-induced beta-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice. J. Biol. Chem. 2012, 287:23024-23033.
37. Meyer-Luehmann M., Spires-Jones T.L., Prada C., Garcia-Alloza M., de Calignon A., Rozkalne A., Koenigsknecht-Talboo J., Holtzman D.M., Bacskai B.J., Hyman B.T. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008, 451:720-724.
38. Mielke J.G., Nicolitch K., Avellaneda V., Earlam K., Ahuja T., Mealing G., Messier C. Longitudinal study of the effects of a high-fat diet on glucose regulation, hippocampal function, and cerebral insulin sensitivity in C57BL/6 mice. Behav. Brain Res. 2006, 175:374-382.
39. Morgan D. Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. Neurochem. Int. 2006, 49:190-194.
40. Muller M., Tang M.X., Schupf N., Manly J.J., Mayeux R., Luchsinger J.A. Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement. Geriatr. Cogn. Disord. 2007, 24:185-192.
41. Nenov M.N., Laezza F., Haidacher S.J., Zhao Y., Sadygov R.G., Starkey J.M., Spratt H., Luxon B.A., Dineley K.T., Denner L. Cognitive enhancing treatment with a PPARgamma agonist normalizes dentate granule cell presynaptic function in Tg2576 APP mice. J. Neurosci. 2014, 34:1028-1036.
42. Nugent D.A., Smith D.M., Jones H.B. A review of islet of Langerhans degeneration in rodent models of type 2 diabetes. Toxicol. Pathol. 2008, 36:529-551.
43. O'Brien J.T. Vascular cognitive impairment. Am. J. Geriatr. Psychiatry 2006, 14:724-733.
44. Ott A., Stolk R.P., Hofman A., van Harskamp F., Grobbee D.E., Breteler M.M. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996, 39:1392-1397.
45. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999, 53:1937-1942.
46. Papadopoulos P., Rosa-Neto P., Rochford J., Hamel E. Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-beta and cerebrovascular pathology. PLOS ONE 2013, 8:e68612.
47. Pappolla M.A., Bryant-Thomas T.K., Herbert D., Pacheco J., Fabra Garcia M., Manjon M., Girones X., Henry T.L., Matsubara E., Zambon D., Wolozin B., Sano M., Cruz-Sanchez F.F., Thal L.J., Petanceska S.S., Refolo L.M. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003, 61:199-205.
48. Pathan A.R., Gaikwad A.B., Viswanad B., Ramarao P. Rosiglitazone attenuates the cognitive deficits induced by high fat diet feeding in rats. Eur. J. Pharmacol. 2008, 589:176-179.
49. Prakash R., Johnson M., Fagan S.C., Ergul A. Cerebral neovascularization and remodeling patterns in two different models of type 2 diabetes. PLOS ONE 2013, 8:e56264.
50. Ramos-Rodriguez J.J., Molina-Gil S., Rey-Brea R., Berrocoso E., Garcia-Alloza M. Specific serotonergic denervation affects tau pathology and cognition without altering senile plaques deposition in APP/PS1 mice. PLOS ONE 2013, 8:e79947.
51. Ramos-Rodriguez J.J., Ortiz O., Jimenez-Palomares M., Kay K.R., Berrocoso E., Murillo-Carretero M.I., Perdomo G., Spires-Jones T., Cozar-Castellano I., Lechuga-Sancho A.M., Garcia-Alloza M. Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. Psychoneuroendocrinology 2013, 38:2462-2475.
52. Ramos-Rodriguez J.J., Pacheco-Herrero M., Thyssen D., Murillo-Carretero M.I., Berrocoso E., Spires-Jones T.L., Bacskai B.J., Garcia-Alloza M. Rapid beta-amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice. J. Neuropathol. Exp. Neurol. 2013, 72:272-285.
53. Razay G., Vreugdenhil A., Wilcock G. The metabolic syndrome and Alzheimer disease. Arch. Neurol. 2007, 64:93-96.
54. Roberson M.R., Harrell L.E. Cholinergic activity and amyloid precursor protein metabolism. Brain Res. Brain Res. Rev. 1997, 25:50-69.
55. Saraswathi V., Ramnanan C.J., Wilks A.W., Desouza C.V., Eller A.A., Murali G., Ramalingam R., Milne G.L., Coate K.C., Edgerton D.S. Impact of hematopoietic cyclooxygenase-1 deficiency on obesity-linked adipose tissue inflammation and metabolic disorders in mice. Metabolism 2013, 62:1673-1685.
56. Sawane M., Kajiya K., Kidoya H., Takagi M., Muramatsu F., Takakura N. Apelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity. Diabetes 2013, 62:1970-1980.
57. Schliebs R., Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J. Neural Transm. 2006, 113:1625-1644.
58. Schrijvers E.M., Witteman J.C., Sijbrands E.J., Hofman A., Koudstaal P.J., Breteler M.M. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology 2010, 75:1982-1987.
59. Serrano-Pozo A., Frosch M.P., Masliah E., Hyman B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011, 1:a006189.
60. Shie F.S., Jin L.W., Cook D.G., Leverenz J.B., LeBoeuf R.C. Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 2002, 13:455-459.
61. Son S.M., Song H., Byun J., Park K.S., Jang H.C., Park Y.J., Mook-Jung I. Altered APP processing in insulin-resistant conditions is mediated by autophagosome accumulation via the inhibition of mammalian target of rapamycin pathway. Diabetes 2012, 61:3126-3138.
62. Stargardt A., Gillis J., Kamphuis W., Wiemhoefer A., Kooijman L., Raspe M., Benckhuijsen W., Drijfhout J.W., Hol E.M., Reits E. Reduced amyloid-beta degradation in early Alzheimer's disease but not in the APPswePS1dE9 and 3xTg-AD mouse models. Aging Cell 2013, 12:499-507.
63. Talbot K., Wang H.Y., Kazi H., Han L.Y., Bakshi K.P., Stucky A., Fuino R.L., Kawaguchi K.R., Samoyedny A.J., Wilson R.S., Arvanitakis Z., Schneider J.A., Wolf B.A., Bennett D.A., Trojanowski J.Q., Arnold S.E. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance. IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 2012, 122:1316-1338.
64. Thambisetty M., Jeffrey Metter E., Yang A., Dolan H., Marano C., Zonderman A.B., Troncoso J.C., Zhou Y., Wong D.F., Ferrucci L., Egan J., Resnick S.M., O'Brien R.J. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol. 2013, 70:1167-1172.
65. van Himbergen T.M., Beiser A.S., Ai M., Seshadri S., Otokozawa S., Au R., Thongtang N., Wolf P.A., Schaefer E.J. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: results from the Framingham Heart Study. Arch. Neurol. 2012, 69:594-600.
66. Weller R.O., Subash M., Preston S.D., Mazanti I., Carare R.O. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol. 2008, 18:253-266.
67. Yang Y., Zhang J., Ma D., Zhang M., Hu S., Shao S., Gong C.X. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J. Alzheimers Dis. 2013, 37:637-648.